SUSTOL® and HTX-011 utilize our proprietary Biochronomer drug delivery technology, which can deliver therapeutic levels of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection. Our Biochronomer technology consists of bioerodible polymers that have been the subject of comprehensive animal and human toxicology studies that have established them to be safe and well tolerated. When injected into subcutaneous tissue, the polymers undergo controlled hydrolysis, resulting in a controlled, sustained release of the pharmacological agent encapsulated within the Biochronomer-based composition.1
Our Biochronomer technology can be applied to a wide range of pharmacological agents across a wide range of therapeutic areas. Furthermore, more than one pharmacological agent can be incorporated into our Biochronomer polymer such that multimodal therapy can be delivered with a single injection.
Other Science and Technology
Heron's scientific team has developed technologies that we believe can significantly improve the clinical profile of certain pharmacological agents. For example, one of these technologies enables certain therapeutics to be delivered in different and preferred routes of administration and without the use of certain excipients that may cause harmful side effects.
Heron's scientific team is continually working on leveraging its know-how and technologies to improve the lives of patients by discovering and developing best-in-class medicines that address unmet medical needs.
1. Ottoboni T et al. Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron. J Exp Pharmacol. 2014;6:15-21.